declares having received honoraria from Novo Nordisk, Eli Lilly, Akebia Therapeutics, Ardelyx, Becton Dickinson, Endologix, FibroGen, GSK, Medtronic, Neovasc, Provention Bio, ReCor, BrainStorm Cell Therapeutics, Alnylam and Intarcia for consulting activities, and research funding to his institution from AbbVie, Esperion, AstraZeneca, CSL Behring, Novartis and Eli Lilly
Arq Bras Endocrinol Metabol (2013) 57:193204.10.1590/S0004-27302013000300005 10 KamijoK
Nature 521 , 99104 (2015)
BMC Clin
This highlights an important reality: the triple agonist mechanism that creates superior efficacy for most individuals may prove intolerable for a subset of users, particularly those sensitive to sympathomimetic or metabolically activating medications
CoolSculpting can target fat on the abdomen, thighs, butt, love handles, upper arm, back, under the chin just about anywhere on the body